Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278692 · ClinicalTrials.gov registry record · NA
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02278692: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02278692 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02278692, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with non-healing and extremely painful skin lesions. At present, there is no effective treatment for calcific uremic arteriolopathy. Vitamin K is an important vitamin for inhibiting vascular calcification. It is known to increase the circulating levels of carboxylated Matrix Gla Protein, a potent inhibitor of vascular calcification. However, the effects of vitamin K supplementation in patients with calcific uremic arteriolopathy are unknown. The purpose of this study is to conduct a pilot randomized controlled trial to examine the effects of oral vitamin K supplementation on circulating levels of anti-calcification factor (carboxylated Matrix Gla Protein) and clinical outcomes in patients with calcific uremic arteriolopathy.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Vitamin K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278692
The ClinicalTrials.gov registry entry for NCT02278692 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02278692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278692 about?
NCT02278692 is a clinical study titled "Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy". Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with non-healing and extremely painful skin lesions. At present, there is no effective...
What is the current status of trial NCT02278692?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2015-03. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02278692?
The interventions under investigation include: Placebo (OTHER), Vitamin K (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02278692?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.